Sign In
Buy CRNX
$33.09
+0.480 (+1.47%)
At Close: Jun 03, 2026
Why Crinetics Pharmaceuticals Stock Was Sliding on Friday
04:16pm, Friday, 07'th Nov 2025
The biotech unveiled its third-quarter results. They didn't meet analyst expectations, but there was good news in the update.
Crinetics Pharmaceuticals, Inc. (CRNX) Q3 2025 Earnings Call Transcript
12:46pm, Friday, 07'th Nov 2025
Crinetics Pharmaceuticals, Inc. ( CRNX ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Gayathri Diwakar - Senior Director of Investor Relations R. Struthers - Founder, Presid
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q3 Loss, Lags Revenue Estimates
06:21pm, Thursday, 06'th Nov 2025
Crinetics Pharmaceuticals, Inc. (CRNX) came out with a quarterly loss of $1.38 per share versus the Zacks Consensus Estimate of a loss of $1.27. This compares to a loss of $0.96 per share a year ago.
Crinetics Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
04:05pm, Thursday, 06'th Nov 2025
PALSONIFY™ (Paltusotine) Launched in the U.S. with Encouraging Early Feedback from Patients and Physicians, and Positive Reimbursement Trends Reiterates Cash Burn of $340-370M and Cash R
Crinetics to Highlight Neuroendocrine Tumor Research Progress at the 2025 North American Neuroendocrine Tumor Society Annual Meeting
08:00am, Thursday, 23'rd Oct 2025
Preliminary analysis of one-year progression-free survival data from Phase 2 study of novel SST2 agonist paltusotine under investigation for carcinoid syndrome demonstrated potential anti-tumor effect
Crinetics Pharmaceuticals Announces October 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:41pm, Friday, 10'th Oct 2025
SAN DIEGO, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on October 10, 2025, the Compensation Committee of the Board of Directors granted non-q
Crinetics Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025
04:05pm, Monday, 06'th Oct 2025
SAN DIEGO, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report third quarter 2025 financial results on Thursday, November 6, 2025 after
Is Crinetics Pharmaceuticals Stock a Buy?
08:30am, Sunday, 28'th Sep 2025
Crinetics Pharmaceuticals (CRNX 27.92%) faces the ultimate biotech paradox: Its newly approved drug Palsonify could either justify the stock's $4.3 billion valuation or expose it as dangerously overpr
Crinetics: FDA Approval And Expansion Of Palsonify In Focus, Maintaining 'Buy' Rating
05:00pm, Friday, 26'th Sep 2025
Crinetics Pharmaceuticals received FDA approval for PALSONIFY, the first daily oral therapy for adults with Acromegaly, addressing a large unmet need. The company has submitted a Marketing Authorizati
Crinetics Pharmaceuticals, Inc. - Special Call
01:57am, Friday, 26'th Sep 2025
Crinetics Pharmaceuticals, Inc. - Special Call Company Participants Gayathri Diwakar - Senior Director of Investor Relations R. Struthers - Founder, President, CEO & Director Dana Pizzuti - Chief Medi
Crinetics Announces FDA Approval of PALSONIFY™ (paltusotine) for the Treatment of Adults with Acromegaly
05:30pm, Thursday, 25'th Sep 2025
Novel nonpeptide SST2 agonist PALSONIFY advances the treatment paradigm as the first once-daily, oral therapy approved by the FDA to treat acromegaly Approval based on data from two pivotal Phase 3 tr
Crinetics Pharmaceuticals Announces September 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Wednesday, 10'th Sep 2025
SAN DIEGO, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on September 10, 2025, the Compensation Committee of the Board of Directors granted no
Crinetics Receives FDA Orphan Drug Designation for Atumelnant in the Treatment of Congenital Adrenal Hyperplasia (CAH)
08:45am, Thursday, 21'st Aug 2025
SAN DIEGO, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) for a
Crinetics Pharmaceuticals Announces August 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Monday, 11'th Aug 2025
SAN DIEGO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on August 10, 2025, the Compensation Committee of the Board of Directors granted non-qu
Crinetics Pharmaceuticals, Inc. (CRNX) Q2 2025 Earnings Call Transcript
11:21am, Saturday, 09'th Aug 2025
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Alan S. Krasner - Corporate Participant Chief Endocrinologist - Corporate
